SciELO - Scientific Electronic Library Online

vol.26 issue1Historia de la Sociedad de Gastroenterología del Perú (Parte I)Coexistencia de Enfermedad Celíaca y Hepatitis Autoinmune: Reporte de un caso y revisión de la literatura author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista de Gastroenterología del Perú

Print version ISSN 1022-5129


ARIZA, Juan Guillermo  and  MARTINEZ, Jairo Andrés. Farmacoeconomía e Investigación de Resultados en el Síndrome de Intestino Irritable: Revisión de la evidencia con Tegaserod. Rev. gastroenterol. Perú [online]. 2006, vol.26, n.1, pp.77-79. ISSN 1022-5129.

Irritable Bowel Syndrome (IBS) is a chronic and episodic disease that affects 14.5% of females in the United States, and its impact decreases the quality of life. On the other hand, IBS consumes a great part of the health budget and develops indirect costs by loss of work productivity. Currently, Tegaserod, an agonist of the number 4 serotonin receptors (5-HT4), indicated for IBS-Constipation treatment, has demonstrated savings while optimizing health resources and improving the quality of life of patients and their work productivity.

Keywords : Pharmacoeconomics; outcomes research; work productivity; Tegaserod.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )